Loading...
Loading...
DFFN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,923.0K |
| Operating I/L | 2,923.0K |
| Other Income/Expense | -5,721.4K |
| Interest Income | 124.7K |
| Pretax | -2,798.3K |
| Income Tax Expense | 5,596.6K |
| Net Income/Loss | -8,395.0K |
Diffusion Pharmaceuticals Inc. is a biopharmaceutical company specializing in developing novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate, Trans Sodium Crocetinate, is designed to improve the diffusion of oxygen to tissues and is being developed to treat COVID-19 disease. The company generates revenue through the development and potential commercialization of its oxygen-enhancing therapies, catering to the healthcare and pharmaceutical industries.
